In brief
In a significant move aimed at lowering healthcare costs, pharmaceutical companies have agreed to decrease the prices of 15 widely-used prescription medications under Medicare. This decision, reached after extensive negotiations, promises substantial financial relief for taxpayers and older adults. While the new prices will take effect in 2027, they are part of ongoing efforts to enhance drug affordability in Medicare programs. The recent agreements also pave the way for future negotiations involving additional drugs and coverage.
NEW YORK (AP) — Pharmaceutical companies have reached an agreement to reduce Medicare prices for 15 prescription drugs after several months of negotiations, a move expected to save taxpayers and seniors billions. Health Secretary Robert F. Kennedy Jr. celebrated this achievement as part of efforts to address the affordability of healthcare for Americans. Although the reported net prices for a 30-day supply are lower, actual costs at pharmacies may vary based on individual Medicare plans and annual spending.As part of the second round of price negotiations mandated by a 2022 law, these agreements will become effective in 2027, bringing the total number of negotiated drugs to 25. Previous agreements under the Biden administration are set to take effect in January 2024.The latest negotiations include popular medications for diabetes and asthma, such as Ozempic and Trelegy Ellipta, which are some of the most costly for Medicare. The Trump administration claims this latest round could save Medicare an estimated $8.5 billion if applied to last year’s expenditures.In addition to the negotiated reductions, the administration implemented a new rule capping out-of-pocket costs for Medicare beneficiaries at $2,000, offering significant relief and an estimated total savings of $685 million for those with drug plans.Critics, however, remain cautious, questioning whether these policies may hinder future pharmaceutical innovations and arguing against government price-setting in the drug market. Next year, Medicare is expected to negotiate prices for another set of 15 drugs.
